DBV Technologies (NASDAQ:DBVT) Shares Gap Down – Time to Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) gapped down prior to trading on Tuesday . The stock had previously closed at $18.29, but opened at $17.50. DBV Technologies shares last traded at $18.1570, with a volume of 43,116 shares trading hands.

Wall Street Analyst Weigh In

DBVT has been the topic of a number of research reports. Cantor Fitzgerald upgraded shares of DBV Technologies to a “strong-buy” rating in a research report on Monday. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Guggenheim initiated coverage on shares of DBV Technologies in a research note on Wednesday, December 3rd. They issued a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, December 8th. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price target (up previously from $20.00) on shares of DBV Technologies in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.05.

DBV Technologies Stock Down 1.0%

The company has a market cap of $727.30 million, a price-to-earnings ratio of -3.50 and a beta of -1.10. The business has a fifty day simple moving average of $14.90 and a 200 day simple moving average of $11.51.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DBVT. Vivo Capital LLC purchased a new position in DBV Technologies during the second quarter worth $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the second quarter valued at $9,659,000. MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the second quarter valued at $9,649,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies during the 2nd quarter worth about $9,315,000. Finally, Millennium Management LLC increased its position in DBV Technologies by 26.1% during the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock worth $3,379,000 after purchasing an additional 69,849 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.